PATENT CLAIM ANALYSIS

Application Number: 16123898
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-08
Patent Classification: ["514", "299000"]

Abstract:
The present invention relates to a method for the treatment of fibrosis, in particular cardiac fibrosis, comprising the administration of an inhibitor of insulin-regulated aminopeptidase (IRAP). Preferable the IRAP inhibitor is chosen from the group including HFI-419, HA-08, AL-40, HFI-437, Val-Tyr-Ile-His-Pro-Phe (otherwise known as angiotensin IV or ANG IV), c[Cys-Tyr-Cys]-His-Pro-Phe, and c[Hcy-Tyr-Hcy]-His-Pro-Phe.

Claim (Index 15):
A method according to claim  1114 , wherein the fibrosis is non-alcoholic steatohepatitis (NASH).

Metadata:
- Claim Count in Document: 5.0
- Percentile: 97.0
- Lexical Diversity: 1.45098
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15747697', '12309010', '14772334', '14317602', '15083836']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.742570035784435
- 35 USC 102 Novelty (BERT): 0.6393654773674695
- Combined Prediction Score: 0.7322495799427385
- Mean Citation Score: 354.693118
- Max Citation Score: 658.3663
- Similarity Product: 524.5649317881226

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test